Record · multiple-sclerosis-research.org
Q&A October is ECTRIMS Month
multiple-sclerosis-research.org · 1 October 2026 · 2 min read
A post on multiple-sclerosis-research.org, published 1 October 2026, has not been cited by any blog yet (corpus.blog, measured 12 October 2026).
A record is what was published and who pointed at it. The text of the post is not shown here: read it at the source, or at its Wayback capture.
0blogs citing
| Period | Blogs | Links |
|---|---|---|
| All time | 0 | 0 |
| Last 90 days | 0 | 0 |
| Last 30 days | 0 | 0 |
| Last 7 days | 0 | 0 |
| Words blogs link it with | 0 |
|---|---|
| External links | 0 |
| Length | 289 |
Cited by
No blog we hold has cited this post yet.
Links from this post
This post links to no other pages.
Similar posts
What US Healthcare Professionals Should Know About Tacabrutideg and the Evolving Landscape of B-Cell Malignancy Care
readability.com
26 Sept 2026
SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-l in acute myeloid leukemia (CertainT-1).
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
A phase 2 trial to evaluate the efficacy and safety of WZTL-002, a third-generation anti-CD19 CAR T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma (ENABLE-2).
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Efficacy and safety of nemtabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Cohort J of the phase 2 BELLWAVE-003 study.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
How Multiple Sclerosis Is Treated
verywellhealth.com
21 Sept 2026
Something wrong here? Report a problem